BIND Therapeutics to Present at the UBS Global Healthcare Conference
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Monday, May 20, 2013 at 3:00 p.m. ET.
Help employers find you! Check out all the jobs and post your resume.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Monday, May 20, 2013 at 3:00 p.m. ET.
Help employers find you! Check out all the jobs and post your resume.